Corcept Therapeutics Inc. Stock
There is an upward development for Corcept Therapeutics Inc. compared to yesterday, with an increase of €0.49 (1.680%).
With 13 Buy predictions and not the single Sell prediction the community is currently very high on Corcept Therapeutics Inc..
With a target price of 122 € there is potential for a 312.86% increase which would mean more than doubling the current price of 29.55 € for Corcept Therapeutics Inc..
Our community identified positive and negative aspects for Corcept Therapeutics Inc. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Corcept Therapeutics Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Corcept Therapeutics Inc. in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corcept Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Inc. | 1.680% | -12.132% | -1.860% | -52.308% | -56.786% | 41.252% | 33.108% |
| Rockwell Medical Inc. | -1.740% | 0.059% | -19.516% | -50.641% | 25.277% | -63.152% | -94.250% |
| Pacira Pharmaceuticals | -4.570% | 2.732% | 13.939% | -22.314% | -12.963% | -51.042% | -69.180% |
| Twist Bioscience Corp | -5.360% | -0.218% | 15.921% | -4.029% | 47.971% | 95.077% | -67.032% |
Comments
Corcept Therapeutics (NASDAQ:CORT) had its price target lowered by analysts at HC Wainwright from $105.00 to $67.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (NASDAQ:CORT) was given a new $105.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (NASDAQ:CORT) had its price target lowered by analysts at HC Wainwright from $145.00 to $90.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CORT provided by MarketBeat
News
Corcept Insider Transaction Explained After Shares Tumble 50% in One Day
On Tuesday, William Guyer, the chief development officer of Corcept Therapeutics (NASDAQ:CORT), exercised and immediately sold 20,000 shares through open-market transactions totaling approximately
